Poland has become one of the most important clinical trial markets in Central and Eastern Europe.
With a population of 38 million, EU aligned regulation, deep investigator experience and a large hospital network, the country offers sponsors a strong combination of patient access, operational quality and research scale.
Poland is especially relevant for oncology, cardiology, dermatology and neurology trials, supported by major academic hospitals, oncology institutes, clinical trial support centres and an increasingly modern digital health infrastructure.
For sponsors planning regional or global studies, Poland is not just a lower cost geography. It is a mature, highly integrated clinical research market with meaningful enrollment capacity and strong site infrastructure.